Effect of sodium zirconium cyclosilicate on the nutritional status of hemodialysis patients: a prospective nested case-control study

doi:10.3877/cma.j.issn.2095-3216.2023.06.002

Abstract

Abstract:

Objective

To observe the effect of sodium zirconium cyclosilicate on the nutritional status of hemodialysis patients with uremia.

Methods

A prospective nested case-control design was used in this study. From January 2022 to June 2022, 21 uremic patients undergoing hemodialysis in our hospital were included as the treatment group, in which sodium zirconium cyclosilicate was orally administered to control blood potassium. At the same time, after propensity score matching was performed based on age, gender, body mass index, baseline blood potassium, and dialysis age, 21 uremic patients were paired as the control group, in which blood potassium was controlled only through dietary restriction method. The two groups were compared in indicators of blood potassium, food frequency, hemoglobin, serum albumin, body mass index, triceps skinfold thickness, and malnutrition-inflammation score, etc.

Results

Compared with the control group, the treatment group showed a decrease in blood potassium and malnutrition-inflammation score (P<0.05), and a significant increase in food diversity, hemoglobin, serum albumin, body mass index, triceps skinfold thickness, and physiological scores of the quality of life questionnaire (P<0.05).

Conclusion

In the hemodialysis patients with uremia, sodium zirconium cyclosilicate could be used to control their hyperkalemia, relax their dietary restrictions, and improve their nutritional status.

Key words: Sodium zirconium cyclosilicate, Hemodialysis, Nutritional status

Jian Liu, Xiaona Zhang, Hongjuan Xu, Limin Peng, Jingjing Song. Effect of sodium zirconium cyclosilicate on the nutritional status of hemodialysis patients: a prospective nested case-control study[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(06): 308-313.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2023.06.002

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2023/V12/I06/308

Figures/Tables 8

References 21

[1]	Naoki F, Shingo H, Masaki M, et al. Relationships of low-grade systemic inflammation and nutritional status with erectile dysfunction severity in men on dialysis [J]. Andrology, 2022, 10(8)：1548-1555.
[2]	刘瑞春，何娜，彭滟. 维持性血液透析患者发生营养不良的影响因素及营养指标对预后的预测价值[J]. 临床合理用药杂志，2022, 15(9): 10-13, 17.
[3]	吴胜利，张桂芝，李寒，等. 维持性血液透析者不同透析间期高钾血症发生率及其危险因素[J]. 国际移植与血液净化杂志，2014, 12(1): 22-24.
[4]	Thazin SM. Effect of dietary counseling on nutritional status of chronic kidney disease patients on hemodialysis [J]. Clin Nutr ESPEN, 2021, 46: S667-S668.
[5]	中国疾病预防控制中心营养与健康所. 中国食物成分表(标准版)[M]. 北京：北京大学医学出版社，2019.
[6]	Aggarwal HK, Jain D, Chauda R, et al. Assessment of malnutrition inflammation score in different stages of chronic kidney disease [J]. Pril (Makedon Akad Nauk Umet Odd Med Nauki), 2018, 39(2-3): 51-61.
[7]	刘怡均，林向英，张燕. 中文版世界卫生组织生存质量测定量表简表用于终末期肾病的信效度验证[J]. 首都医科大学学报，2021, 42(4): 635-641.
[8]	Ahmed S, Rahman T, Ripon M, et al. A food frequency questionnaire for hemodialysis patients in Bangladesh (BDHD-FFQ): development and validation [J]. Nutrients, 2021, 13(12): 4521.
[9]	Goyal A, Spertus JA, Gosch K, et al. Serum potassium levels and mortality in acute myocardial infarction [J]. JAMA, 2012, 307(2): 157-164.
[10]	Collins AJ, Pitt B, Reaven N, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes [J]. Am J Nephrol, 2017, 46(3): 213-221.
[11]	茹巧美，任国平，张学兵. 15种不同产地梅干菜营养功能与有害成分分析[J]. 中国调味品，2020, 45(9): 150-155.
[12]	毕惠惠，毛伟伟，李海霞，等. 小麦钾离子通道蛋白基因TaAKT1的功能分析[J]. 麦类作物学报，2018, 38(12): 1391-1399.
[13]	饶宝蓉，罗海燕，杜中军，等. 不同香蕉品种钾离子吸收动力学研究[J]. 热带作物学报，2009, 30(11): 1612-1617.
[14]	朱宏，梁克红，郭子轩，等. 黑猪肉与普通猪肉的营养成分对比[J]. 食品工业，2021, 42(3): 342-346.
[15]	陈佐忠，黄德华. 自然条件下大针茅草原几种主要植物氮、磷、钾、铁含量的季节动态[J]. 植物生态学与地植物学学报，1989, 13(4): 325-331.
[16]	刘露，杨新鑫，张丽梅，等. 磷锌配施对水稻生长、产量和养分吸收分配的影响[J]. 华中农业大学学报，2021, 40(2): 156-165.
[17]	黄雯. 终末期肾脏病透析患者水溶性维生素的丢失[J]. 中国血液净化，2015, 14(5): 294-296.
[18]	王萍，蒋更如. 血液透析对新诊断终末期肾脏疾病患者血清氨基酸的影响[J]. 上海交通大学学报(医学版), 2008, 28(10): 1341-1342, 1349.
[19]	丁苗佳，沈水娟，吴佳盈. 新型口服降钾药物环硅酸锆钠治疗慢性肾脏病高钾血症临床进展[J]. 中国医药科学，2021, 11(21): 66-69.
[20]	李蒙，李正翔，袁恒杰. 治疗高钾血症药物环硅酸锆钠[J]. 天津药学，2020, 32(1): 61-65.
[21]	Levien TL, Baker DE. Sodium zirconium cyclosilicate [J]. Hosp Pharm, 2019, 54(1): 12-19.

项目	治疗组	对照组	t/χ²值	P值
性别(男/女)	15/6	15/6	0	1
年龄(岁)	50.95±6.32	51.05±6.12	－0.2	0.984
基线血钾(mmol/L)	6.72±0.82	6.78±0.78	0.389	0.699
身体质量指数	18.16±3.08	18.21±2.94	－1.223	0.229
透析龄(年)	1.57±0.87	1.61±0.82	－0.365	0.717
尿素清除指数	1.47±0.16	1.42±0.13	0.995	0.326
甲状旁腺素(pg/ml)	255.23±91.54	224.8±77.73	1.161	0.252
每周促红素用量(u)	7095.24±2488.06	7523.81±2522.28	－0.554	0.582
每月蔗糖铁用量(g)	4.90±2.18	4.62±2.17	0.424	0.674

项目	治疗组	对照组	t/χ²值	P值
性别(男/女)	15/6	15/6	0	1
年龄(岁)	50.95±6.32	51.05±6.12	－0.2	0.984
基线血钾(mmol/L)	6.72±0.82	6.78±0.78	0.389	0.699
身体质量指数	18.16±3.08	18.21±2.94	－1.223	0.229
透析龄(年)	1.57±0.87	1.61±0.82	－0.365	0.717
尿素清除指数	1.47±0.16	1.42±0.13	0.995	0.326
甲状旁腺素(pg/ml)	255.23±91.54	224.8±77.73	1.161	0.252
每周促红素用量(u)	7095.24±2488.06	7523.81±2522.28	－0.554	0.582
每月蔗糖铁用量(g)	4.90±2.18	4.62±2.17	0.424	0.674

组别	例数	用药后24 h	用药后28 d	用药后3个月
对照组	21	4.52±0.59	4.73±0.77	4.45±1.28
治疗组	21	3.95±0.32^a	3.82±0.24^a	3.98±0.50^a
F值			37.458
P值			<0.001

组别	例数	用药后24 h	用药后28 d	用药后3个月
对照组	21	4.52±0.59	4.73±0.77	4.45±1.28
治疗组	21	3.95±0.32^a	3.82±0.24^a	3.98±0.50^a
F值			37.458
P值			<0.001

组别	身体质量指数				肱三头肌皮褶厚度(mm)
组别	基线	3个月后	t值	P值	基线	3个月后	t值	P值
治疗组	18.16±3.08	21.52±2.22^ab	－4.915	<0.001	8.15±2.45	12.21±3.27^ab	－4.187	<0.001
对照组	18.21±2.94	20.13±1.96^b	－2.242	0.036	8.31±2.19	10.21±2.92^b	－3.392	0.003
t值	－0.022	2.796			0.354	2.305
P值	0.982	0.008			0.725	0.026

Please choose a citation manager

Content to export